[11] Driven by a growing number of studies implicating its role in the pathogenesis of cardiovascular disease and injury, antagonism of the NLRP3 inflammasome is an increasing focus in vascular medicine.[11b] MCC950 was the first developed small molecule inhibitor which covalently binds to and prevents NLRP3 oligomerization. This evidence concerns the gene NLRP3 and cardiovascular disorder.